Nice USRM article today! Like this part >>
This includes the aggressive expansion of an additional 12 stem cell treatment centers and clinics in the U.S. The company, based in Florida, had recently expanded to Miami Beach, but now the plans call for truly national expansion. USRM will set up stem cell treatment centers in huge metropolitan areas like Dallas, Chicago, Atlanta and Denver. Moreover, the company has emphasized that it will focus squarely on “revenue-generating programs” that are treating patients right now.
For investors, this is the equivalent of a company using lemons to make lemonade. The company will need to wait longer now to get FDA approval for its two key products – MyoCell and AdipoCell – but it is focused on creating value for investors in the short- and mid-term. And there is certainly a track record here of creating value. In Q1 2017, the company significantly grew revenue (from $710,000 to $1.15 million) and also boosted its cash position from $62,000 to $268,000.
And there’s one more potential catalyst for USRM, and that’s a new $5 million private equity investment from General American Capital Partners. In making the investment, the private equity firm cited the potential “exponential growth in the stem cell industry,” which could grow to become a $170 billion market opportunity by 2020.
Looking forward, there’s a lot to like about USRM. Yes, the stock may have gotten a little frothy in the early months of 2017. But now it looks like any pullback could be a chance to get in early on a stem cell leader. This is a company with a proven scientific team, a technology in Phase II/III trials, a positive revenue and cash flow position, and the backing of a respected private equity firm.
News 
Market Data 
Discover 
